Neurochemical Research

, Volume 17, Issue 9, pp 917–922 | Cite as

Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms

  • Andrew W. Procter
  • Paul T. Francis
  • Gary C. Stratmann
  • David M. Bowen
Original Articles

Abstract

Behavioural symptoms of Alzheimer's disease, such as aggression, may determine the care patients required. Most postmortem neurochemical studies have been of institutionalized patients and conclusions drawn from these may not be valid for all patients. We have shown that serotonin 2 receptors are not lost from 12 of the 13 areas of cerebral cortex examined in the patients assessed to be free of aggressive symptoms. This has been interpreted as representing the relative preservation of cortical interneurones. In contrast choline acetyltransferase activity was reduced in all areas whereas serotonin content was reduced in only 2 of the 4 areas examined.

Key Words

Alzheimer's disease behavior serotonin cerebral cortex 

Abbreviations

AD

Alzheimer's disease

ChAT

choline acetyltransferase activity

GABA

gamma-amino butyric acid

5-HT

serotonin

SLIR

somatostatin-like immuno-reactivity

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosen, W. G., Mohs, R. C., and Davis, K. L. 1984. A new rating scale for Alzheimer's Disease. Am. J. Psychiatry 141:1356–1364.Google Scholar
  2. 2.
    Hope, R. A., and Fairburn, C. G. 1990. The nature of wandering in dementia: a community based study. Int. J. Geriat. Psychiatry 5:239–245.Google Scholar
  3. 3.
    Wilkins, R. H., and Brody, I. A. 1969. Alzheimer's Disease. Arch. Neurol. 21:109–110.Google Scholar
  4. 4.
    Sanford, J. 1975. Tolerance of disability in elderly dependents by supporters at home: its significance for hospital practice. Br. Med. J. iii:471–473.Google Scholar
  5. 5.
    Chenoweth, B., and Spencer, B. 1986. Dementia: the experience of family caregivers. Gerontologist 26:267–272.Google Scholar
  6. 6.
    Procter, A. W., and Bowen, D. M. 1988. Aging, the cerebral neocortex and psychiatric disorder. In: Pages 3–20, Finch C. E., Davies, P. (eds) Banbury Report 27: Molecular Neuropathology of Aging. Cold Spring Harbor Laboratory, Cold Spring Harbor.Google Scholar
  7. 7.
    Palmer, A. M., Stratmann, G. C., Procter A. W., and Bowen, D. M. 1988. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann. Neurol. 23:616–620.Google Scholar
  8. 8.
    Bowen, D. M., Najlerahim, A., Procter, A. W., Francis, P. T., and Murphy, E. 1989. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc. Natl. Acad. Sci. U.S.A. 86:9504–9508.Google Scholar
  9. 9.
    Palmer, A. M., Francis, P. T., Benton, J. S., Sims, N. R., Mann, D. M., Neary, D., Snowden, J. S., and Bowen, D. M. 1987. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J. Neurochem. 48:8–15.Google Scholar
  10. 10.
    Procter, A. W., Lowe, S. L., Palmer, A. M., Francis, P. T., Esiri, M. M., Stratmann, G. C., Najlerahim, A., Patel, A. J., Hunt, A., and Bowen, D. M. 1988. Topographical distribution of neurochemical changes in Alzheimer's disease. J. Neurol. Sci. 84:125–140.Google Scholar
  11. 11.
    McKhann, G., Drachman, D., Folstein, M. F., Katzman, R., Price, D., and Stadlan, E. M. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:939–944.Google Scholar
  12. 12.
    Lowe, S. L., Francis, P. T., Procter, A. W., Palmer, A. M., Davison, A. N., and Bowen, D. M. 1988. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain 3:785–799.Google Scholar
  13. 13.
    Burns, A., Jacoby, R., and Levy, R. 1990. Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behavior. Br. J. Psychiatry 157:86–94.Google Scholar
  14. 14.
    Burns, A., Jacoby, R., and Levy, R. 1990. Psychiatric phenomena in Alzheimer's disease III: Disorders of mood. Br. J. Psychiatry 157:81–86.Google Scholar
  15. 15.
    Teri, L., Larson, E. B., and Reifler, B. V. 1988. Behavioral disturbance in dementia of the Alzheimer's type. J. Am. Geriatr. Soc. 36:1–6.Google Scholar
  16. 16.
    Knesevitch, J. W., Martin, R. L., Berg, L., and Danziger, W. 1983. Preliminary report on affective symptoms in the early stages of senile dementia of the Alzheimer type. Am. J. Psychiatry 140:233–235.Google Scholar
  17. 17.
    Merriam, A. E., Aronson, M. K., Gaston, P., Wey, S-L., and Katz, I. 1988. The psychiatric symptoms of Alzheimer's disease. J. Am. Geriatr. Soc. 36:7–12.Google Scholar
  18. 18.
    Reifler, B. V., Larson, E., and Hanley, R. 1982. Coexistence of cognitive impairment and depression in geriatric outpatients. Am. J. Psychiatry 139:623–626.Google Scholar
  19. 19.
    Birkett, D. P. 1972. The psychiatric differentiation of senility and arteriosclerosis. Br. J. Psychiatry 120:321–325.Google Scholar
  20. 20.
    Reisberg, B., Borenstein, J., Salob, S. P., Ferris, S. H., Fransen, E., and Georgotas, A. 1987. Behavioral symptoms in Alzheimer's Disease: Phenomenology and treatment. J. Clin. Psychiatry 48 [5, Suppl]:9–15.Google Scholar
  21. 21.
    Swearer, J. M., Drachman, D. A., O'Donnell, B. F., and Mitchell, A. L. 1988. Troublesome and disruptive behaviors in dementia. Relationships to diagnosis and disease severity. J. Am. Geriatr. Soc. 36:784–790.Google Scholar
  22. 22.
    Ryden, M. B. 1988. Aggressive behavior in persons with dementia who live in the community. Alzheimer. Dis. Assoc. Disord. 2:342–355.Google Scholar
  23. 23.
    Procter, A. W., Palmer, A. M., Francis, P. T., Lowe, S. L., Neary, D., Murphy, E., Doshi, R., and Bowen, D. M. 1988. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J. Neurochem. 50:790–802.Google Scholar
  24. 24.
    Cross, A. J, Crow, T. J., Johnson, J. A, Bloom, S. R., and Corsellis, J. A. N. 1984. Serotonin receptor changes in dementia of Alzheimer type. J. Neurochem. 43:1574–1581.Google Scholar
  25. 25.
    Perry, E. K., Perry, R. H., Candy, J. M., Fairbairn, A. F., Blessed, G., Dick, D. J., and Tomlinson, B. E. 1984. Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer's disease: comparisons with Parkinson's disease. Neurosci. Lett. 51:353–357.Google Scholar
  26. 26.
    Reynolds, G. P., Arnold, L., Rossor, M. N., Iversen, L. L., Mountjoy, C. Q., and Roth, M. 1984. Reduced binding of [3H] ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type. Neurosci. Lett. 44:47–51.Google Scholar
  27. 27.
    Dewar, D., Graham, D. I., and McCulloch, J. 1990. 5 HT2 receptors in dementia of Alzheimer type: a quantitative autoradiographic study of frontal cortex and hippocampus. J. Neural Transm. Park. Dis. Dement. Sect. 2:129–137.Google Scholar
  28. 28.
    Swigar, M. E., Benes, F. M., Rothman, S. L. G., Opsahl, C., and Dowds, M. M. 1985. Behavioral correlates of computed tomographic (CT) scan changes in older psychiatric patients. J. Am. Geriatr. Soc. 33:96–1034.Google Scholar
  29. 29.
    Tork, I., and Hornung, J-P. 1990. Raphe nuclei and the serotonergic system.in Pages 1001–1022, Paxinos, G. (ed.) The human nervous system. Academic Press, Sandiago.Google Scholar
  30. 30.
    Francis, P. T., Pangalos, M. N., Pearson, R. C. A., Middlemiss, D. N., Stratmann, G. C., and Bowen, D. M. 1991. 5-HT1A but not 5-HT2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J. Pharmacol. Exp. Therapeut. (in press).Google Scholar
  31. 31.
    Bowen, D. M., Francis, P. T., Procter, A. W., and Young, A. B. 1991. Treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. (in press).Google Scholar
  32. 32.
    Nyth, A. L., and Gottfries, C. G. 1990. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Brit. J. Psychiat. 157:894–901.Google Scholar
  33. 33.
    Hermann, C., Stern, R. G., Losonzey, M. F., and Jaff, S. 1991. Diagnostic and Pharmacological Approaches in Alzheimer's disease. Drugs & Aging 2:144–162.Google Scholar
  34. 34.
    Dresse, A., and Scuvee-Moreau, J. 1988. Electrophysiological effects of tianeptine on rat locus coeruleus, raphe dorsalis, and hippocampus activity. Clin. Neuropharmacol. 11:551–558.Google Scholar
  35. 35.
    Lawlor, B. A., Sunderland, T., Mellow, A. M., Hill, J. L., Molchan, S. E., and Murphy, D. L. 1989. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease: A controlled study. Arch. Gen. Psychiat. 46:542–549.Google Scholar

Copyright information

© Plenum Publishing Corporation 1992

Authors and Affiliations

  • Andrew W. Procter
    • 1
    • 2
  • Paul T. Francis
    • 1
  • Gary C. Stratmann
    • 1
  • David M. Bowen
    • 1
  1. 1.Miriam Marks Department of NeurochemistryInstitute of NeurollogyLondon
  2. 2.Department of PsychiatryUMDS-Guy's HospitalLondon

Personalised recommendations